Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00567047 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

A Phase 1 study of Type 2 Diabetes, sponsored by Novartis.

Completed
Registry status
Phase 1
Development phase
96
Enrollment target
6
Study locations

NCT00567047 is a Phase 1 study of Type 2 Diabetes that has completed, run by Novartis. The registered enrollment target is 96 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00567047, a Phase 1 study of Type 2 Diabetes, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 1
Development phase
96 participants
Enrollment target
6
Study locations

Study Summary

This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG vildagliptin

Study Locations (6)

Florida

  • Novartis Investigator Site - Miami
  • Novartis Investigator Site - Orlando

Minnesota

  • Novartis Investigator Site - Minneapolis

Tennessee

  • Novartis Investigator Site - Knoxville

Virginia

  • Novartis Investigator Site - Richmond

Other

  • Novartis Investigator Site - Kiel

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2007-07
Phase Phase 1

Sponsor

Novartis

265 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00567047

The ClinicalTrials.gov registry entry for NCT00567047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which vildagliptin is the first listed.

NCT00567047 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Minnesota, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00567047 about?

NCT00567047 is a clinical study titled "Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment". This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

What is the current status of trial NCT00567047?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2007-07.

What conditions does trial NCT00567047 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT00567047?

The interventions under investigation include: vildagliptin (DRUG).

Who is sponsoring clinical trial NCT00567047?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00567047 being conducted?

This trial has 6 study locations across Florida, Minnesota, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.